Maria (aka Dr. Maria J. De Jesus) developed several breakthrough technologies as Senior Scientist at the Swiss Federal Institute of Technology (EPFL) in Lausanne. These inventions have had profound effects on cell line development, and some have attained global application in early R&D work towards clinical manufacturing of biologics. Both founders are often invited to speak at conferences on the manufacturing of proteins with recombinant cells in bioreactors.

Why ExcellGene? A focus on great science yields great results.

Starting from work on the very first pharmaceutical proteins made in CHO cells, we`ve always been driven by science and innovative thinking. As a result, we have unparalleled knowledge on protein expression in bioreactors, and a complete grasp on the control parameters influencing performance in large-scale bioreactors. Our twin expertise in biology and engineering enables us to successfully conclude the most challenging protein expressions and virus vector productions.

Remarkably productive cell hosts.

Our transient and stable protein expression technologies and processes are based on proprietary CHOExpress™ cells – a uniquely productive and robust CHO cell host. We see similar performance for HEKExpress™ (HEK cells) and for insect cells (FlyExpress™).

Experts from transfection to manufacturing.

We cover the pharmaceutical value chain from DNA construction and transfection to scalable process and manufacture for clinical use.

Our clients

We serve biotech solutions worldwide

Clients choose us due to our singular scientific expertise from DNA to product and a highly personalized, communicative approach towards each project. Through this, we ensure that your project goals are delivered reliably and in good time.

ExcellGene SA news

CEPI’s $3.6B Initiative with ExcellGene: Single Molecule for Global Defense in COVID Trials

Contact supplier